Antiviral resistance monitoring capability and capacity for SARS-CoV-2 and influenza within the EU/EEA
Take our survey
Share your feedback in our short survey and help us improve publications at ECDC. Your input is valuable!
This report presents the results from a survey among 30 EU/EEA countries.
Executive Summary
- More than half of EU/EEA countries perform antiviral resistance testing for influenza, and three countries perform antiviral resistance testing for SARS-CoV-2.
- Most of the countries are interested in extending their antiviral resistance testing, either to influenza or SARS-CoV-2 or to both.
- Antiviral resistance monitoring of new virus variants could improve the appropriate clinical use of antiviral drugs.
- For SARS-CoV-2, most countries rely on genotypic analyses for antiviral resistance testing, with very few countries performing both genotypic and phenotypic analyses.
- For influenza, most countries perform both genotypic and phenotypic analyses.
- Whole Genome Sequencing is becoming the most commonly used approach for antiviral resistance analysis, allowing rapid identification, monitoring and assessment of mutations creating antiviral resistant variants.
